Efficacy of Once-Yearly Intravenous Zoledronic Acid for Osteopenia
- Author:
Chang Ho SUNG
1
;
Wan Sik SEO
;
Ye Soo PARK
Author Information
1. Department of Orthopedic Surgery, Guri Hospital, Hanyang University College of Medicine, Guri, Korea. hyparkys@hanyang.ac.kr
- Publication Type:Original Article
- Keywords:
Zoledronic acid;
Osteopenia;
Efficacy;
FRAX
- MeSH:
Bone Density;
Bone Diseases, Metabolic;
Bone Resorption;
Hip;
Humans;
Osteocalcin;
Osteoporotic Fractures;
Risk Assessment
- From:Journal of Korean Society of Osteoporosis
2013;11(3):114-118
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVES: To assess the clinical efficacy of once-yearly treatment with Zoledronic acid in patients with osteopenia. MATERIALS AND METHODS: From June 2009 to November 2011, patients diagnosed with osteopenia were applied to fracture risk assessment tool (FRAX). Among them, 40 patients who showed high possibility of osteoporotic fracture were selected and treated with intravenous zoledronic acid once-yearly. At the baseline and after one year of injection of zoledronate, we measured the changes in the bone mineral density (BMD) and bone turnover markers In addition, we analyzed the side effects and thereby assessed the drug safety.
